NOTICE
TO READERS: The press releases, presentations,
printed remarks, footage and publications that are included on our
website are for historical purposes only. The information contained
in these materials should be considered accurate only as of the date
of the relevant item. This information may change over time, and
visitors to this website should not assume that the information contained
in these materials remains accurate at a later time. Oculus Innovative
Sciences, Inc. disclaims any intention to supplement, update or revise
any of the information contained in these materials.
These press releases about Oculus Incorporated are sorted by date,
with the most recent at the top. You will need the free Adobe®
Reader® to view the PDFs. |
Corporate
Background
.....................................................................................
Download
the Oculus backgrounder information sheet.
(PDF: 141 KB)
Current Press
Releases
.....................................................................................
June 3rd, 2009
FDA
Clears Expanded Label Claim for Oculus Innovative Sciences' Lead Microcyn® Wound
Care Product
May 27th, 2009
Oculus
Innovative Sciences Announces Fiscal Fourth Quarter Financial Results
and Corporate Update Release and Conference Call
May 26th, 2009
Oculus
Innovative Sciences Receives FDA Clearance for Microcyn® Skin and
Wound Gel
May 3rd, 2009
Oculus
Innovative Sciences Reports Significant Increase in Sales of its Approved
Microcyn® Product in Mexico as H1N1 Flu (Swine Flu) Spreads
April 28th, 2009
Oculus
Innovative Sciences Presents Business Update Prior to Financial West
Investor Conference
March 18th, 2009
Oculus
Innovative Sciences Sponsoring RID Symposium at SHEA Conference in
San Diego
March 18th, 2009
Oculus
Innovative Sciences to Exhibit Its Newest Advances in Microcyn® Wound
Care at DF Con 09 on March 19-21
February 11th, 2009
Oculus
Innovative Sciences Reports Third Quarter Product Revenue Up 19% with
a $2.6 Million Reduction in Operating Expenses
February 9th, 2009
Oculus
Innovative Sciences to Present at the Roth Capital Partners 21st Annual
OC Growth Stock Conference
February 8th, 2009
Oculus
Innovative Sciences' Security Holders Exercise Rights or Invest in
Company as Result of Recently Announced Strategic Investment by VetCure,
Inc.
Archived Press Releases
.....................................................................................
September 4, 2008
Oculus
Innovative Sciences Holds Successful End-of-Phase II Meeting with FDA
for Microcyn® Technology
August 7, 2008
Oculus
Innovative Sciences to Present at Canaccord Adams 28th Annual Global
Growth Conference
August 5, 2008
Oculus
Innovative Sciences Reports 59% Increase in First Quarter Product Revenue
July 29, 2008
Oculus
Innovative Sciences Announces Fiscal First Quarter Financial Results
and Corporate Update Release and Conference Call
July 16, 2008
Oculus
Innovative Sciences' CEO and Founder Named One of Pharmaceutical Executive's
2008 "Emerging Pharma Leaders"
July 1, 2008
Oculus
Innovative Sciences Announces Positive Results from Abstract Evaluating
the Use of Microcyn® Technology in Treatment of Atopic Dermatitis
» Click Here For More
Archived Press Releases
Upcoming Events
.....................................................................................
For a full list of trade shows
and conferences, click here.
Clinical Studies
.....................................................................................
The Journal for Vascular Ultrasound
(December 2006)
Nonsurgical
Management of Chronic Wounds in
Patients With Diabetes
(PDF: 108 KB)
Wounds (September
2006)
Super-Oxidized
Solution (SOS) Therapy for Infected Diabetic
Foot Ulcers
(PDF: 256 KB)
Diabetic Microvascular Complications
Today
(May/June 2006)
Superoxidized Water Improves
Wound Care Outcomes in Diabetic Patients
(PDF: 192 KB)
Journal of Hospital Infection (2005)
Microcyn®:
a novel super-oxidized water with neutral pH and disinfectant activity
(PDF: 256 KB)
White Papers
.....................................................................................
Effect
of Electrolyzed Water on Wound Healing
(PDF: 550 KB)
|
Media Coverage
.....................................................................................
June 11, 2009
PressDemocrat.com
Investors
take new look at Oculus
(PDF: 44 KB)
March 22,
2009
WLFI.com: Simple treatment helps
local resident
Oxygen
and water calms allergies
September
10, 2008
Medical Device Daily
Oculus
cuts costs in advance of U.S. launch of Microcyn
(PDF: 88 KB)
August 1, 2008
FOX Business
News: America's Nightly Scoreboard
The following video is available in Windows®
Media Player, and RealPlayer®.
Click on the links below to view the videos in
your preferred format.
June 9, 2008
North Bay Business Journal
Device
expected to greatly widen Oculus’ market
(PDF: 124 KB)
April 16, 2008
NASDAQ CEO
Signature Series: Interview with Hoji Alimi
The following video is available in Windows®
Media Player, and RealPlayer®.
Click on the links below to view the videos in your preferred format.
February 27, 2008
Bloomberg
Oculus
Treatment Effective Against Diabetic Foot Infections
(PDF: 16 KB)
June 2007
International Immunopharmacology
Super-oxidized
solution inhibits IgE-antigen-induced degranulation and cytokine release
in mast cells
(PDF: 740 KB)
June 4, 2007
Diabetes Health
It's
a Wash: New Antimicrobial Solution Called Microcyn May Help Cure Diabetic
Ulcers
May 24, 2007
The Daily Mail
Scientists
create 'miracle water' that kills infections and MRSA
(PDF: 228 KB)
May 24, 2007
BBC News
Firm
makes 'healing super-water'
(PDF: 84 KB)
May 23, 2007
BBC Radio Five Live
Hoji
Alimi speaks about the Microcyn® Technology
on BBC Radio Five Live. Click to listen now.
Note: If you have problems accessing the MP3 file, PC
users may need to right click on the the link and "Save Target As." After
you have saved the file, open it in your preferred media player such
as Windows® Media
Player or RealPlayer®.
May 23, 2007
New Scientist
Bugs
struck down by 'super-oxidised' water
(PDF: 352 KB)
March 2007
The International Journal of Lower
Extremity Wounds
Clinical
Outcomes of Wide Postsurgical Lesions in the Infected
Diabetic Foot Managed...
(PDF: 232 KB)
September 2006
Wounds
Super-Oxidized
Solution (SOS) Therapy for Infected Diabetic Foot Ulcers
(PDF: 256 KB)
August 2006
Podiatry Today
Emerging
Innovations In Treatment
(PDF: 244 KB)
January 2006
Wounds
Clinical
Experience with a New, Stable, Super-Oxidized Water in Wound Treatment
(PDF: 528 KB)
August 5, 2005
The New York Times
As
New Products Arrive, Wound Care Sales Grow
(PDF: 64 KB)
June, 2005
Dermatology Times
Super-oxidized
water kills bacteria; demonstrates potential for healing
(PDF: 88 KB)
June 6, 2005
Outlook India
H2O's
Healing Touch - Chronic wounds now find a cure, courtesy Microcyn®
(PDF: 495 KB)
June 1, 2005
Coast to Coast
Hoji
Alimi speaks about the Microcyn® Technology on Coast to Coast AM
radio. Click to listen now.
Note: If you have problems accessing the MP3 file, PC
users may need to right click on the the link and "Save Target As." After
you have saved the file, open it in your preferred media player such
as Windows® Media Player or RealPlayer®.
Oculus on FOX News
The following video is available in Windows® Media Player, and RealPlayer®.
Click on the links below to view the videos in your preferred format.
May 17, 2005
Paul
Harvey mentions Microcyn® on his Tuesday noon show. Listen now
using Windows Media Player.
May 16, 2005
Super
Water Kills Bugs Dead -
A California company has figured out how to use two simple materials....
(PDF: 65 KB)
March 26, 2005

'Ion
man' seeks to tap acceptance for his water solution -
A souped-up form of water has been overlooked
as a killer of lethal viruses and bacteria....
(PDF: 120 KB)
Oculus on ABC News
The following video is available in Apple® QuickTime, Windows® Media Player, and RealPlayer®.
Click on the links below to view the videos in your preferred format.


February 10, 2005
Read
What Forbes Magazine says about the Microcyn® Technology.
(PDF: 64 KB)
November 9, 2004
PESTICIDE.NET
- Super Oxidized Water Registered By EPA As A
Hard-Surface Disinfectant
(PDF: 120 KB) |
FAIR
USE NOTICE: These articles and news reports may contain copyrighted
material, the use of which may or may not have been specifically authorized
by the copyright owner. This material is being made available in efforts
to advance the understanding of scientific and medical issues. It is
believed that this constitutes a 'fair use' of any such copyrighted
material as provided for in section 107 of the US Copyright Law. In
accordance with Title 17 U.S.C. Section 107, the material on this site
is distributed without profit to those who have expressed a prior interest
in receiving the included information for research, comment, discussion
and educational purposes by visiting the Oculus web site. If you wish
to use copyrighted material from these reports for purposes of your
own that go beyond 'fair use', you must obtain permission from the
copyright owner.
This web page contains forward-looking
statements that involve risks and uncertainties. These forward-looking
statements relate to, among other things, regulatory approvals, plans
and timing for the introduction of our products, statements about future
market conditions, supply and demand conditions, revenues, gross margins,
operating expenses, profits and other expectations, intentions and
plans that are not historical fact.
Our expectations as expressed at
this web site depend upon our ability to develop, manufacture, obtain
regulatory approval and supply and sell products that meet defined
specifications. When used, the words "plan," "expect," "believe,"
and similar expressions generally identify forward-looking statements.
These statements reflect our current expectations. They are subject to
a number of risks and uncertainties, including, but not limited to, changes
in technology and in the health sciences market. In light of the many
risks and uncertainties surrounding this market, you should understand
that we cannot assure you that the forward-looking statements contained
herein will be realized. |